"I am assuming that since it has been stated many times online that Bioheart has had over 100 million dollars put into R&D."
Well, they've diluted out to about 600 MILLION shares along the way to pay for that too. As BigAl just aptly pointed out- they, BHRT has a Accumulated deficit (paid in capital deficit) of (117,954,949$$$)
That's $117 MILLION dollars sunk into the company, which now has about an $8.X million dollar market cap, while still carrying about $10 million in current debt.
I'd say the vast, vast majority of that capital has been paid via selling common stock to the general public, IMO. Not sure how much can be attributed to say Hart, for example. He formed and created Northstar, LLC and they put up some collateral to keep a defaulted loan from being "called in" (aka bankruptcy)- but they, Northstar also has received a boat load of shares of stock for that, interest payments, loan payments, etc. They also got granted all the preferred shares the company currently has, 20 million with all voting control power as the preferred shares have a 25 to 1 vote over common holders and they also got a lien on nearly everything Bioheart does own, can own, would ever invent, sell in the future, etc.
See the 10-K filing end of 2013 for the lien statement - it's a doozy IMO.
" In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property
rights of any nature, as well as the results of all clinical trials, know-how for preparing Myblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
News 
Market Data 
Discover 
